Efficacy of antipsychotics for delirium in cancer patients: a systematic review
Not Applicable
- Conditions
- Cancer
- Registration Number
- JPRN-UMIN000051843
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
1. Duplicate publications 2. Conference proceedings
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of delirium
- Secondary Outcome Measures
Name Time Method Death, tumbling, falls, extrapyramidal symptoms and somnolence
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antipsychotic efficacy in cancer-related delirium?
How do antipsychotics compare to standard-of-care treatments for delirium in oncology patients?
Are specific biomarkers predictive of antipsychotic response in delirium among cancer patients?
What adverse events are associated with antipsychotic use for delirium in advanced cancer populations?
What combination therapies or alternative drugs are evaluated alongside antipsychotics in delirium management for oncology patients?